News | November 18, 2022
Apollo launches national program to promote rational use of antibiotics
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The company is making its entry into the Hyderabad market through its unique asset-light business model
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Revenue from operations up 26% to Rs. 768 crores
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Subscribe To Our Newsletter & Stay Updated
